Thursday 14 November 2024

The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's

Biotechnology
Simon Wentworth
17 July 2023
pharma_letter_podcast_24

More on this story...

Biotechnology
The Pharma Letter Podcast — Episode 23 — AAIC preview with Eisai deputy CCO Michael Irizarry
6 July 2023
Biotechnology
The week in pharma: action, reaction and insight – week to July 21, 2023
23 July 2023
Pharmaceutical
Lotus to market Corium's Alzheimer's patch in Southeast Asia
11 August 2023
Biotechnology
Coya Therapeutics expands COYA 302 into Alzheimer’s disease
21 February 2024


Companies featured in this story

More ones to watch >


Today's issue

Positive results for Microbion’s new diabetic foot ulcer drug
Pharmaceutical
Positive results for Microbion’s new diabetic foot ulcer drug
14 November 2024
Pharmaceutical
ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline
14 November 2024
Pharmaceutical
Momentum flagging, a Phase III data win spurs tirzepatide
14 November 2024
Pharmaceutical
Merck KGaA shares slip on cautious outlook
14 November 2024
Biotechnology
AC Immune Phase II ACI-7104.056 success in Parkinson’s
14 November 2024
Biotechnology
The Pharma Letter Podcast — Episode 29 — How can we use AI to program antibodies?
14 November 2024
Pharmaceutical
Swiss approval for LEO Pharma’s Anzupgo
14 November 2024

Company Spotlight

A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.




More Features in Biotechnology

AC Immune Phase II ACI-7104.056 success in Parkinson’s
14 November 2024
The Pharma Letter Podcast — Episode 29 — How can we use AI to program antibodies?
14 November 2024
FDA nod for AADC deficiency gene therapy from PTC
14 November 2024
CAR-T cell therapies to pave way for drug-free remission in lupus care
14 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze